Royalty Pharma (NASDAQ:RPRX) Upgraded by StockNews.com to “Buy”

StockNews.com upgraded shares of Royalty Pharma (NASDAQ:RPRX) from a hold rating to a buy rating in a report issued on Tuesday.

RPRX has been the subject of a number of other reports. The Goldman Sachs Group raised their price objective on shares of Royalty Pharma from $50.00 to $51.00 and gave the company a buy rating in a research note on Wednesday, August 14th. Morgan Stanley raised their price objective on shares of Royalty Pharma from $48.00 to $51.00 and gave the company an overweight rating in a research note on Thursday, July 11th. Finally, UBS Group lowered shares of Royalty Pharma from a buy rating to a neutral rating and set a $28.00 price objective for the company. in a research note on Monday, June 3rd. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, Royalty Pharma currently has a consensus rating of Moderate Buy and a consensus target price of $42.00.

Royalty Pharma Stock Down 1.6 %

Shares of Royalty Pharma stock opened at $27.54 on Tuesday. The company has a debt-to-equity ratio of 0.78, a current ratio of 9.35 and a quick ratio of 9.35. The company has a 50-day moving average of $28.00 and a 200 day moving average of $28.00. The firm has a market cap of $16.34 billion, a price-to-earnings ratio of 20.55, a PEG ratio of 4.17 and a beta of 0.46. Royalty Pharma has a 1 year low of $25.20 and a 1 year high of $31.66.

Royalty Pharma (NASDAQ:RPRX) last released its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported $0.96 earnings per share for the quarter, beating analysts’ consensus estimates of $0.95 by $0.01. The business had revenue of $537.00 million during the quarter, compared to analyst estimates of $600.83 million. Royalty Pharma had a net margin of 30.08% and a return on equity of 23.61%. During the same period last year, the business earned $0.85 EPS. As a group, sell-side analysts anticipate that Royalty Pharma will post 4.04 earnings per share for the current fiscal year.

Royalty Pharma Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, September 13th. Stockholders of record on Friday, August 16th were paid a $0.21 dividend. The ex-dividend date of this dividend was Friday, August 16th. This represents a $0.84 dividend on an annualized basis and a dividend yield of 3.05%. Royalty Pharma’s dividend payout ratio is presently 62.69%.

Institutional Trading of Royalty Pharma

Large investors have recently made changes to their positions in the stock. Versant Capital Management Inc grew its stake in shares of Royalty Pharma by 5,215.0% in the second quarter. Versant Capital Management Inc now owns 1,063 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 1,043 shares during the period. Gladius Capital Management LP purchased a new position in shares of Royalty Pharma in the second quarter worth approximately $32,000. Fidelis Capital Partners LLC bought a new stake in Royalty Pharma during the first quarter valued at approximately $46,000. GAMMA Investing LLC grew its position in Royalty Pharma by 172.5% during the first quarter. GAMMA Investing LLC now owns 1,638 shares of the biopharmaceutical company’s stock valued at $50,000 after buying an additional 1,037 shares during the period. Finally, EverSource Wealth Advisors LLC grew its position in Royalty Pharma by 79.8% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,807 shares of the biopharmaceutical company’s stock valued at $51,000 after buying an additional 802 shares during the period. 54.35% of the stock is currently owned by institutional investors.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.